Sudden hemothorax as a rare initial manifestation of bronchiectasis under a direct oral anticoagulant

• Published in: Surgical case reports 2022-09, Vol.8 (1), p.175-175, Article 175
• Main Authors: Nakayama, Hikaru, Uebayashi, Asuka, Yagi, Shota, Iizuka, Shuhei, Otsuki, Yoshiro, Nakamura, Toru
• Format: Article
• Language: English
• Subjects: Anticoagulants; Bronchiectasis; Case Report; Case reports; Direct oral anticoagulant; Hemothorax; Medicine; Medicine & Public Health; Pleural effusion; Surgery; Tomography
• ISSN: 2198-7793; 2198-7793
• DOI: 10.1186/s40792-022-01536-0

Background A hemothorax as the initial manifestation of bronchiectasis is extremely rare. We report a case of a sudden hemothorax due to exacerbation of clinically latent bronchiectasis under a direct oral anticoagulant. Case presentation A 77-year-old woman presented with chest pain and a fever noted since the day before. She had stage G3 chronic kidney disease and received edoxaban for paroxysmal atrial fibrillation. She had no history of trauma or respiratory symptoms. A chest computed tomography revealed a mass with a surrounding opacity in the right lower lobe with a pleural effusion. Conservative treatment was chosen because of the stable vital signs and her respiratory condition. Her oxygen saturation dropped 7 h later with progressive anemia. Repeated chest computed tomography showed a worsening pulmonary opacity and pleural effusion. She underwent a right lower lobectomy successfully. The histopathological findings suggested that the preceding infection of the subpleural focal bronchiectasis caused the bleeding. In addition, a steep caliber change between the subpleural focal bronchiectasis and proximal normal branch may have caused an intraluminal pressure gradient resulting in a peripheral discharge causing a pleural rupture with a hemothorax. Conclusion The sudden hemothorax could have been the initial manifestation of bronchiectasis. Particular attention should be paid to peripherally localized bronchiectasis even if it is without any clinical symptoms, especially in patients with a comorbidity such as a susceptibility to infections and the use of direct oral anticoagulants.